Related Experiment Video
Updated: Jul 8, 2025
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Tumor nano-lysate activates dendritic cells to evoke a preventative immune response
Jenna A Dombroski1, Abigail R Fabiano1, Samantha V Knoblauch1
1Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, United States.
Abstract:
A tumor nano-lysate "TNL" vaccine comprised of sonicated 4T1 cells was developed, characterized and implemented for the prevention of triple-negative breast cancer. This study aimed to gain a better understanding of the immune response behind the success of the vaccine in vivo, through use of ex vivo and in vivo assays. Here, we analyze the activation of various immune cells isolated from healthy mouse spleens and find that antigen-presenting cells (APCs) such as dendritic cells (DCs) are being activated following 24 h incubation with 1:10 mg TNL/mg splenocytes. These cells were further explored to determine the pathway by which activation is occurring, and it was observed that TNL are phagocytosed by DCs to activate NF-kB and c-Fos pathways, resulting in enhanced cytokine release after 24 h. An in vivo temporal analysis was performed in mice to understand the immune response at 1, 3, 7 and 10 days after one 100 μL dose of TNL consisting of 105 sonicated 4T1 cells via cardiac puncture and splenocyte and peripheral blood mononuclear cell (PBMC) analysis. Changes were observed for up to one week. A multiple dose study was performed comparing mice that were vaccinated with one dose of TNL administered every ten days for 3 doses total, as well as a PBS vehicle control. Survival for TNL-vaccinated mice was enhanced compared to the PBS control, and there was an average delay of 10 days in the onset of metastasis. The differences between the groups at the end of the study demonstrate the potential for TNL as a preventative therapeutic.
Insights
A novel tumor nano-lysate (TNL) vaccine shows promise in preventing triple-negative breast cancer by activating immune cells. This immunotherapy enhances survival and delays metastasis in preclinical models.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Triple-negative breast cancer (TNBC) remains a significant health challenge with limited therapeutic options.
- Tumor nano-lysate (TNL) vaccines represent a novel approach for cancer prevention.
- Understanding the underlying immune mechanisms is crucial for optimizing TNL efficacy.
Purpose of the Study:
- To investigate the immune response elicited by a TNL vaccine derived from sonicated 4T1 cells.
- To elucidate the cellular and molecular pathways involved in TNL-mediated immune activation.
- To evaluate the preventative potential of TNL against triple-negative breast cancer in vivo.
Main Methods:
- Ex vivo analysis of immune cell activation (dendritic cells, APCs) upon TNL exposure.
- Investigation of TNL phagocytosis and downstream signaling pathways (NF-kB, c-Fos) in dendritic cells.
- In vivo temporal immune response monitoring in mice post-TNL vaccination.
- Assessment of survival and metastasis delay in a TNL-vaccinated mouse model compared to a control group.
Main Results:
- TNL activated antigen-presenting cells (APCs), including dendritic cells (DCs), leading to enhanced cytokine release.
- DCs phagocytosed TNL, activating NF-kB and c-Fos pathways.
- In vivo studies showed immune system changes for up to one week after a single TNL dose.
- Multiple TNL doses significantly improved survival rates and delayed metastasis onset by an average of 10 days compared to PBS controls.
Conclusions:
- TNL vaccines effectively activate key immune cells involved in anti-tumor responses.
- The observed immune activation pathways provide mechanistic insight into TNL efficacy.
- TNL demonstrates significant potential as a preventative immunotherapy for triple-negative breast cancer.
More Related Videos
11:48Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...